Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javle

Showing results (261-270 of 343) with videos related to

Pageof 35
Sort By:
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Cancer|June 1, 2016
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinomaJordan M Cloyd, Christopher H Crane, Eugene J Koay, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
BJU International|November 19, 2010
Early prostate cancer--which treatment do men prefer and why?Carmel N Anandadas, Noel W Clarke, Susan E Davidson, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
The Oncologist|February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal CancersNatalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?Awalpreet S Chadha, Guan Liu, Hsiang-Chun Chen, et al.
Pageof 35

Showing results (261-270 of 343) with videos related to

Sort By:
Pageof 35
NPJ Precision Oncology|July 31, 2024
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterationsSarina A Piha-Paul, Chieh Tseng, Cheuk Hong Leung, et al.
Cancer|June 1, 2016
Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinomaJordan M Cloyd, Christopher H Crane, Eugene J Koay, et al.
Cancer Discovery|February 15, 2024
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived XenograftsTimothy P DiPeri, Kurt W Evans, Bailiang Wang, et al.
Oncotarget|November 21, 2017
Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experienceJennifer B Goldstein, Chad Tang, Kenneth R Hess, et al.
BJU International|November 19, 2010
Early prostate cancer--which treatment do men prefer and why?Carmel N Anandadas, Noel W Clarke, Susan E Davidson, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
The Lancet. Oncology|August 2, 2021
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket studyMilind Javle, Mitesh J Borad, Nilofer S Azad, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2024
Limited Independent Follow-Up with Germline Testing of Variants Detected in <i>BRCA1</i> and <i>BRCA2</i> by Tumor-Only SequencingCarol J Nowlen, Molly Daniels, Burak Uzunparmak, et al.
The Oncologist|February 8, 2024
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal CancersNatalie Y L Ngoi, Tin-Yun Tang, Catia F Gaspar, et al.
International Journal of Radiation Oncology, Biology, Physics|January 10, 2017
Does Unintentional Splenic Radiation Predict Outcomes After Pancreatic Cancer Radiation Therapy?Awalpreet S Chadha, Guan Liu, Hsiang-Chun Chen, et al.
Pageof 35